The C-POST trial showed a disease-free survival benefit with adjuvant Libtayo for high-risk cutaneous squamous cell carcinoma, potentially influencing future standard care. Immunotherapy remains the ...
CINCINNATI (WKRC) - As cooler months approach, many may not consider it the right time to check for skin cancer risks. However, Dr. Elizabeth Muennich from Ohio's Dermatology and Skin Care Associates ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results